FDA Approval Targets Rare Kidney Disease - Takeaways - MDSpire

FDA Approval Targets Rare Kidney Disease

Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.

  • By

  • Kathryn Wighton

  • April 14, 2026

  • 2 min

Share

  • 1

    The FDA approved FILSPARI (sparsentan) for reducing proteinuria in patients with focal segmental glomerulosclerosis aged 8 and older.

  • 2

    Focal segmental glomerulosclerosis is a rare kidney disorder that can lead to kidney failure due to progressive glomerular scarring.

  • 3

    Sparsentan's approval expands its use beyond immunoglobulin A nephropathy, potentially benefiting over 100,000 patients in the US.

  • 4

    In the phase 3 DUPLEX trial, sparsentan showed a 46% reduction in proteinuria compared to 30% with irbesartan at 108 weeks.

  • 5

    Sparsentan requires liver function monitoring due to hepatotoxicity risk and is contraindicated in pregnancy due to embryo-fetal toxicity.

Original Source(s)

FDA Approval Targets Rare Kidney Disease

  • by Kathryn Wighton

  • April 14, 2026

Related Content

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.